Herpes simplex virus

Division of Pediatric Infectious Disease, University of Virginia, Charlottesville, Virginia, United States
Pediatrics in Review (Impact Factor: 0.82). 04/2004; 25(3):86-93. DOI: 10.1542/pir.25-3-86
Source: PubMed
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Primary care patients who are sexual with another person—or who have ever in the past been sexual with another person—deserve a thorough history to review sexual patterns and events and to assess present risk of sexually transmitted infections (STIs) and illnesses. The STI history is akey part of the new patient work-up, and those initial findings help set the interval for future assessments. For celibate patients, ask at least annually, “Has anything changed since you last told me you are not sexual with anyone?” For patients with one or more sex partners, repeat the STI history anytime you ask history questions of any kind. For patients with a history of risky behavior or an STI diagnosis, assess risk taking at every encounter, look for opportunities to praise and support safer sex steps, and intervene promptly when you discover behavioral risk taking or clinical evidence of infection.
    12/2007: pages 279-293;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An andrographolide analogue, 3, 19-isopropylideneandrographolide (IPAD), exerts an inhibitory effect on replication of wild-type herpes simplex virus serotype 1 (HSV-1). In this study, we examined the anti-viral activity of IPAD on HSV wild types (HSV-1 strain KOS and HSV-2 clinical isolate) and HSV-1 drug-resistant strains (DRs). Synergistic effects of IPAD with acyclovir (ACV) were also evaluated. MTT and cytopathic effect (CPE) reduction assays were performed to determine cytotoxicity and anti-viral activities, respectively. A combination assay was used to determine synergistic effects of IPAD and ACV. Presence of viral DNA and protein in experimental cells was investigated using the polymerase chain reaction and western blotting, respectively. A non-cytotoxic concentration of IPAD (20.50 μM) completely inhibited CPE formation induced by HSV wild types and HSV-1 DRs after viral entry into the cells. The anti-HSV activities included inhibition of viral DNA and protein synthesis. The minimum inhibitory concentrations of ACV for HSV wild types and HSV-1 DRs were 20.20 and 2,220.00 μM, respectively. Combination of ACV with IPAD showed synergistic effects in inhibition of CPE formation, viral DNA and protein synthesis by HSV wild types as well as HSV-1 DRs. For the synergistic effects on HSV wild types and HSV-1 DRs, the effective concentrations of ACV were reduced. These results showed the inhibitory potential of IPAD on HSV wild types and HSV-1 DRs and suggested that IPAD could be used in combination with ACV for treatment of HSV-1 DRs infections.
    BMC Complementary and Alternative Medicine 12/2015; 15(1):591. DOI:10.1186/s12906-015-0591-x · 1.88 Impact Factor
  • Klinische Pädiatrie 01/2005; 217:110-119. DOI:10.1055/s-2005-872505 · 1.90 Impact Factor

Full-text (2 Sources)

Available from
Jun 2, 2014